Last reviewed · How we verify
Uniplas
Uniplas is a Biologic drug developed by Octapharma. It is currently in discontinued development. Also known as: Blood group independent, universally applicable, prion-depleted, solvent/detergent treated, human pooled plasma.
Uniplas is a treatment being studied for Thrombotic Thrombocytopenic Purpura (TTP) in a clinical trial. The trial compares the safety and efficacy of Uniplas to Cryosupernatant plasma in treating TTP.
At a glance
| Generic name | Uniplas |
|---|---|
| Also known as | Blood group independent, universally applicable, prion-depleted, solvent/detergent treated, human pooled plasma |
| Sponsor | Octapharma |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uniplas CI brief — competitive landscape report
- Uniplas updates RSS · CI watch RSS
- Octapharma portfolio CI
Frequently asked questions about Uniplas
What is Uniplas?
Who makes Uniplas?
Is Uniplas also known as anything else?
What development phase is Uniplas in?
Related
- Manufacturer: Octapharma — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Blood group independent, universally applicable, prion-depleted, solvent/detergent treated, human pooled plasma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing